Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.04 +0.84 (+1.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
40 41 Next >
News headline image
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows ↗
Roche Holdings AG's  (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)  
Via Benzinga
News headline image
Peering Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
News headline image
Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing ↗
CEOs of Eli Lilly And Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Sanofi SA (NASDAQ: SNY), and PBM e 
Via Benzinga
News headline image
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody ↗
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have  
Via Benzinga
News headline image
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns ↗
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies. 
Via Investor's Business Daily
News headline image
Sanofi (SNY) Q1 2023 Earnings Call Transcript ↗
SNY earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
News headline image
Earnings Outlook For Sanofi ↗
 
Via Benzinga
Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
What Wall Street Is Saying About Disney Ahead Of Earnings ↗
Disney set to report amid fights with writers and DeSantis. 
Via Talk Markets
News headline image
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics ↗
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult  
Via Benzinga
News headline image
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
News headline image
7 Blue-Chip Stocks to Buy in May 2023 ↗
While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy. 
Via InvestorPlace
News headline image
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating  
Via Benzinga
Sanofi (NASDAQ: SNY) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
AbbVie Stock Shows Improved Relative Price Strength ↗
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see. 
Via Investor's Business Daily
News headline image
7 Stock Upgrades and Downgrades Alerts You Cannot Ignore ↗
Analyst stock upgrades and downgrades caught the market's attention in the last week and putting investors on notice for buys and sells. 
Via InvestorPlace
News headline image
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals ↗
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public... 
Via Benzinga
News headline image
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront ↗
Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently... 
Via Benzinga
News headline image
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
News headline image
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales ↗
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
News headline image
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet' ↗
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
News headline image
Earnings Scheduled For April 27, 2023 ↗
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
News headline image
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗
 
Via Benzinga
News headline image
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
News headline image
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
News headline image
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
News headline image
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.